RxDoctor Payments Data

Lawrence Brent, MD

Rheumatology · Philadelphia, PANPI 1043271729

Payments from drug & device makers

$21,987in general payments, 2019–2025

Across 40 payments — averaging $549.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$8K
  • AstraZeneca$5K
  • GSK$5K
  • Pfizer$4K
  • Novartis$464
  • Henry Schein, Inc.$51
  • plus $59 from 2 others
$1,862in research payments, 2019–2025

Across 10 payments — averaging $186.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$2K

What the payments were for

  • Consulting fees$14,69467%
  • Speaking & faculty fees$3,85018%
  • Travel & lodging$2,13710%
  • Food & beverage$1,2936%
  • Education$130%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson11$7,661
AstraZeneca10$5,117
GSK9$4,773
Pfizer3$3,863
Novartis4$464
Henry Schein, Inc.1$51
Amgen1$31
Aurinia Pharma U.S., Inc.1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,987 in reported general payments places this provider in the 75th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$27,842
Medicare patients
129
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab49$416,646
Orencia ClickjectAbatacept43$372,997
Humira PenAdalimumab30$262,502
IlarisCanakinumab/Pf13$246,373
TremfyaGuselkumab16$240,484
RinvoqUpadacitinib34$213,623
Enbrel SureclickEtanercept22$181,188
KevzaraSarilumab24$129,562
Xeljanz XrTofacitinib Citrate20$105,003
OrenciaAbatacept12$66,802
XeljanzTofacitinib Citrate12$62,814
OtezlaApremilast12$59,284
OlumiantBaricitinib11$30,006
Celecoxib313$16,540
Mycophenolate Mofetil73$11,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlaris$464$246,37313 claims
Johnson & JohnsonTremfya$7,661$240,48416 claims
PfizerXeljanz$3,863$62,81412 claims
AmgenOtezla$31$59,28412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →